Abbott Wins Over Right to Challenge DexCom Patents at Tribunal (Correct)

The Federal Circuit ruled that an Abbott Laboratories unit focused on diabetes care wasn’t barred by a settlement agreement from challenging a rival’s patents at the US Patent and Trademark Office.

The patent dispute between Abbott Diabetes Care Inc. and DexCom Inc., the maker of competing continuous glucose monitoring systems, dates to 2006. The companies ended an initial round of feuding with a settlement and cross-license agreement signed in 2014. The patent peace wouldn’t last, however, and the two parties filed competing suits in 2021.

In response to DexCom’s suit, Abbott filed petitions challenging five of the San Diego company’s ...